In a secondary analysis of a double-blind , placebo-controlled trial in which early post-menopausal women ( N = 1054 ) with normal bone density or osteopenia were randomized to infusion of zoledronate 5 mg ( N = 703 ) or placebo ( N = 351 ) , we analyzed significant adverse ocular events occurring within 3 months .